Although more data about the potential of ICC as target cells will be needed before the clinical implications of these findings are elucidated, KIT-positive ICCs may be one of the therapeutic target cells to reduce bladder overactivity and blocking c-kit receptor may offer a new therapeutic strategy for OAB treatment in the future. Here, KIT is linked to intrahepatic cholangiocarcinoma.